The field of gene cloning remained a largely unexplored area until 1973, when A. C. Y. Chang, H. W. Boyer, R. B. Helling and Stanley N. Cohen reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, the evolution of genome engineering techniques has allowed for alterations in the genome of microorganisms, thereby enabling the production of substances having various research and therapeutic applications. DNA cloning, which is a highly regulated method, is widely acknowledged and employed in many laboratories throughout the world. Specifically, during the COVID-19 pandemic, several well-known pharmaceutical and biopharmaceutical companies, as well as synthetic biology market players, have stepped forward and contributed to the research and development of a variety of products, such as test kits, treatment solutions, and vaccines to combat the coronavirus infection using synthetic biology. Based on the requirement, a variety of approaches, such as traditional cloning, PCR cloning, ligation independent cloning, seamless cloning and recombinational cloning, can be used to clone the DNA. Despite several advancements in the field of synthetic biology, the DNA cloning process is associated with various challenges, such as requirement of large amounts of expensive vectors for cloning, different reagents and longer time duration for the completion of process.
In order to overcome these drawbacks, innovators in the pharmaceutical industry have undertaken several efforts for identifying and developing ways to improve the process of DNA cloning. Among other alternatives, the use of DNA cloning kits has emerged as a viable option for various drug developers and academic / research institutes to overcome the challenges associated with the traditional DNA cloning methods. Presently, more than 250 DNA cloning kits are available in the market. These cloning kits are affordable, easy to use and produce high quality results in short duration. Further, more than 3,200 patents and 4,000 research articles have been published for DNA cloning technologies in the past few years; this is indicative of the innovative efforts of the stakeholders engaged in this domain. Driven by the increasing demand for gene therapies and the introduction of novel and advanced DNA cloning technologies, the DNA cloning market is anticipated to witness steady growth in the coming years.
The “Synthetic Biology: DNA Cloning Market, 2022-2035: Distribution by Type of Cloning Method (Blunt End Cloning, Ligase Independent Cloning, PCR Cloning, Seamless Cloning, TA Cloning and Other Methods), End-Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End-Users) and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of DNA cloning kits and reagents over the next decade. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
One of the key objectives of the report was to estimate the future growth potential of synthetic biology: DNA cloning (kits and reagents) market, over the coming decade. We have provided informed estimates on the financial evolution of the market for the period 2022-2035. For this purpose, we have segmented the future opportunity across types of cloning methods (blunt end cloning, ligase independent cloning, PCR cloning, seamless cloning, TA cloning and other methods), end-users (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users) and key geographical regions (North America, Europe, Asia Pacific, Latin America, and Middle East and North Africa). In order to account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.
The opinions and insights presented in the report were influenced by survey inputs from various experienced stakeholders in the industry.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
In order to overcome these drawbacks, innovators in the pharmaceutical industry have undertaken several efforts for identifying and developing ways to improve the process of DNA cloning. Among other alternatives, the use of DNA cloning kits has emerged as a viable option for various drug developers and academic / research institutes to overcome the challenges associated with the traditional DNA cloning methods. Presently, more than 250 DNA cloning kits are available in the market. These cloning kits are affordable, easy to use and produce high quality results in short duration. Further, more than 3,200 patents and 4,000 research articles have been published for DNA cloning technologies in the past few years; this is indicative of the innovative efforts of the stakeholders engaged in this domain. Driven by the increasing demand for gene therapies and the introduction of novel and advanced DNA cloning technologies, the DNA cloning market is anticipated to witness steady growth in the coming years.
Scope of the Report
The “Synthetic Biology: DNA Cloning Market, 2022-2035: Distribution by Type of Cloning Method (Blunt End Cloning, Ligase Independent Cloning, PCR Cloning, Seamless Cloning, TA Cloning and Other Methods), End-Users (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Other End-Users) and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of DNA cloning kits and reagents over the next decade. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
In addition to other elements, the report includes:
- A detailed assessment of the current market landscape of DNA cloning kits, featuring information on the kit components (enzyme mix, vector, buffer, ligase and primer), number of reactions (between 1-35, between 36-50 and more than 50), type of cloning method used (ligation independent cloning, TA cloning, blunt cloning and in-fusion seamless cloning), type of fragment(s) cloned (multiple fragments, long fragments and short oligonucleotides), cloning time (5 minutes, between 10-30 minutes, between 31-60 minutes and more than 60 minutes), overlaps recognized, efficacy (80-100%, between >90->99%, >=98%) and kit shelf life (between 1-10 months, between 11-20 months, more than 20 months) and kit price (1-500 USD, 501-1500 USD, 1501-2500 USD, more than 2500 USD). In addition to this, the chapter features information on DNA cloning kit providers and a detailed analysis based on several relevant parameters, such as year of establishment, company size, region of headquarters, location of headquarters, company size and region of headquarters and leading players (in terms of number of products).
- A detailed assessment of the current market landscape of DNA cloning regents, featuring information on reagent unit size (less than 500, 500-2,000 and more than 2,000), reagent concentration (less than 5 units/μl, 5-50 units/μl and more than 50 units/μl) reagent components (polymerase, buffers and additional components), exonuclease activity (5′->3′ exonuclease activity and 3’-> 5’ exonuclease activity), product overhangs (3'A, blunt, 3', 5', 3'/blunt, 3'A/ blunt, 3'-dA and 5'/3'), storage temperature (-20°C,-30°C to -10 °C,-5 °C to -30 °C and -25 °C to -15 °C) and reagent price (less than USD 100, USD 100-500 and more than USD 500). In addition, the chapter features analysis related to DNA cloning reagents providers based on parameters, such as year of establishment, company size, region of headquarters, location of headquarters, company size and region of headquarters and leading players (in terms of number of products).
- Elaborate profiles of prominent players offering DNA cloning kits and reagents (shortlisted based on number of products), based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to its financials (if available), DNA cloning kit portfolio, DNA cloning reagent portfolio, recent developments and an informed future outlook.
- An analysis of over 4,400 peer-reviewed scientific articles related to DNA cloning, published since 2018, based on several parameters, such as year of publication, type of article, type of publication, emerging focus areas, most popular publishers, most popular authors, and most popular journals.
- An analysis of more than 1,200 grants related to DNA cloning, since 2017, based on several parameters, such as year of grant, amount of grant, administrating institute center, support period, type of grant application, purpose of grant, activity code, study section awarded, emerging focus areas, most popular program officers, popular recipient organizations, popular recipient organizations and geographical distribution of recipient organizations.
- An in-depth analysis of over 3,400 patents that have been filed / granted for DNA cloning, between 2017-2021, based on multiple parameters, such as type of patent, publication year, application year, geography, CPC symbols, emerging focus areas, issuing authority involved, type of applicant, leading industry players, leading non-industry players, leading patent assignees, patent benchmarking analysis, patent characteristics and geography, patent age. It also includes a detailed patent valuation analysis and information on the leading patents.
- A case study on the DNA cloning service providers, featuring information and detailed analysis based on their year of establishment, company size, location of headquarters, region of headquarters and company size and region of headquarters.
- A case study on the general overview of advancements in DNA cloning, covering details related to the current and future trends in the domain.
One of the key objectives of the report was to estimate the future growth potential of synthetic biology: DNA cloning (kits and reagents) market, over the coming decade. We have provided informed estimates on the financial evolution of the market for the period 2022-2035. For this purpose, we have segmented the future opportunity across types of cloning methods (blunt end cloning, ligase independent cloning, PCR cloning, seamless cloning, TA cloning and other methods), end-users (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and other end-users) and key geographical regions (North America, Europe, Asia Pacific, Latin America, and Middle East and North Africa). In order to account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.
The opinions and insights presented in the report were influenced by survey inputs from various experienced stakeholders in the industry.
The report features detailed insights of respondents who participated in the study (in alphabetical order):
- Jesús C. Morales (Business Development Manager, Canvax Biotech)
- Stephen Lan (Vice President, SBS Genetech)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the key players engaged in the development of DNA cloning kits and reagents?
- What is the focus area of various publications related to DNA cloning?
- Which research institutes have received relatively more grants for projects related to DNA cloning?
- How has the intellectual property landscape of DNA cloning evolved over the last several years?
- Which region(s) are likely to occupy the maximum market share in DNA cloning kits market?
- Which factors are likely to influence the evolution of this market?
- How is the current and future market opportunity related to DNA cloning kits likely to be distributed across key market segments?
- Who are the key players offering services related to DNA cloning?
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE: DNA CLONING KITS
5. MARKET LANDSCAPE: DNA CLONING REAGENTS
6. DNA CLONING KITS AND REAGENTS: COMPANY PROFILES
7. PUBLICATION ANALYSIS
8. GRANT ANALYSIS
9. PATENT ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11. CASE STUDY: DNA CLONING SERVICE PROVIDERS
12. EVOLUTION OF DNA CLONING
14. EXECUTIVE INSIGHTS
List Of Figures
List Of Tables
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbFrontier
- Applied Biological Materials
- ABP Biosciences
- Addgene
- Agilent Technologies
- America Diagnostics
- Amid Biosciences
- AMSBIO
- Applied Biosystems
- AstraZeneca
- Biocompare
- Bio-Fab Research
- Bioline (acquired by Meridian Bioscience)
- Biomiga
- Bioneer
- Bionics
- Bio-Rad Laboratories
- BioServ
- BIOSS Centre for Biological Signalling Studies
- Blue Heron Biotech (acquired by Eurofins Genomics)
- Broad Institute
- Boston University Medical Campus (BUMC)
- Cambridge Bioscience
- Canvax Biotech
- Cellecta
- Cellomics Technology
- Charles River Laboratories
- Chromous Biotech
- Codex DNA
- Columbia University
- Columbia University Irving Medical Center (CUIMC)
- Commonwealth Scientific and Industrial Research Organisation (CSIRO)
- Creative Biogene
- Creative Biolabs
- Credora
- Curia (formerly AMRI)
- Cytiva
- Dana-Farber Cancer Institute
- Dow AgroSciences
- Duke University
- DuPont
- Elpis Biotech
- Enzynomics
- Epoch Life Science
- Eurofins
- Exonbio
- Fisher Scientific
- Fraser International College (FIC)
- Fred Hutchinson Cancer Research Center
- Friedrich Miescher Institute for Biomedical Research
- GCC Biotech
- Gemini Biosciences
- GENAXXON bioscience
- GeneCust
- Genei
- geneOmbio Technologies
- General Biosystems
- Genentech
- GENEWIZ
- GenScript
- Harvard University
- Hologic
- IBA Lifesciences
- Innoprot
- Intact Genomics
- Invitrogen
- J. Craig Venter Institute (JCVI)
- Jackson Laboratory
- Johns Hopkins University
- Labtoo
- Lamda Biotech
- Leland Stanford Junior University
- Massachusetts Institute of Technology
- MedGenome
- Merck
- Meridian Bioscience
- Molecular Cloning Laboratories (MCLAB)
- Molecular Diagnostic Services
- National Cancer Institute (NCI)
- National Center for Advancing Translational Sciences (NCATS)
- National Center for Complementary and Integrative Health (NCCIH)
- National Human Genome Research Institute (NHGRI)
- National Institute for Health and Medical Research (INSERM)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institute of Child Health and Human Development (NICHD)
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Environmental Health Sciences (NIEHS)
- National Institute of General Medical Sciences (NIGMS)
- National Institute of Mental Health (NIMH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- National Institute on Drug Abuse (NIDA)
- National Institute on Minority Health and Health Disparities (NIMHD)
- New England Biolabs
- Novozymes
- National Heart, Lung, and Blood Institute (NHLBI)
- Novozymes
- Nuclear Energy Institute (NEI)
- NZYTech
- Office of the Director (OD)
- OriCiro Genomics
- OriGene Technologies
- Patheon
- Pioneer
- Precision BioSciences
- Promega
- Protein Ark
- QIAGEN
- Quintara Biosciences
- Roche
- SBS Genetech
- SciGenom Labs
- Sentebiolab
- Signosis
- Stanford University
- Synbio Technologies
- Synovance
- Takara Bio
- Texas A&M Health Science Center
- Thermo Fisher Scientific
- Trenzyme
- Twist Bioscience
- Unity Lab Services
- University of Alabama
- University of California
- University of Helsinki
- University of Minnesota
- University of North Carolina
- University of Pennsylvania
- University of Queensland
- University of Vienna
- University of Washington
- Vazyme
- VectorBuilder
- Veterans Affairs (VA)
- WZ Biosciences
- Yale University
- Zymerge
Methodology
LOADING...
